May 31, 2013 at 11:12 AM EDT
UPDATE: Jefferies Assumes Coverage on Sequenom at Buy on Unappreciated Value
In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Sequenom (NASDAQ: SQNM ) with a Buy rating, but lowered the price target from $7.50 to $6.00. In the report, Jefferies noted, “SQNM's flagship MaterniT21 test continues to ramp at a blistering clip, formal reimbursement contracts are building,
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here